Fresh analysis indicates that people who discontinue blockbuster slimming jabs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise plans.
Findings released in a prominent health publication shows that while overweight people often shed substantial amounts of their body weight while using the jabs, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"People purchasing these drugs should be informed of the potential of fast rebound weight gain when the therapy concludes," warns expert Dr. Susan Jebb.
This pace of regain suggests a return to starting weight in about 18 months.
Analyzing Therapies
The study, which examined 37 of studies involving thousands of participants, contrasted the results of these new drugs with older methods.
The team emphasize that people who shed pounds through dieting generally see a more gradual creep back—perhaps 100 grams monthly—after stopping.
Explaining the Fast Regain
Experts suggest the mode of action of the jabs explains the amplified rebound.
The injections copy a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making excessive eating a significant risk."
An Ongoing Issue?
The NHS suggest the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts say that, given the likelihood of weight regain, the therapy is often life-long.
This opinion is supported by pharmaceutical companies, who say that the findings "highlight the persistent nature of obesity," comparing it to managing conditions like hypertension.
Patient Testimonies
People who have come off the jabs report a sudden resurgence of hunger.
"I experienced a trigger that goes on and I was suddenly starving," said one woman.
This difficulty is worsened if individuals have not developed sustainable lifestyle or habit modifications during treatment.
Significant Use
Figures indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is greater among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are effective tools for weight loss, they are not a permanent solution and lasting health benefits relies on integrated behavioural support.
